4 recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 4, Not yet recruiting 1, Terminated 1 |
Follow Hepatocellular Carcinoma Non-Resectable: new trials by email Literature Review of Hepatocellular Carcinoma Non-Resectable trials Research Report on Hepatocellular Carcinoma Non-Resectable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma Magnesium Microspheres, cTACE - Hepatocellular Carcinoma Non-Resectable | Phase 3 | Not yet recruiting | InnoBM Pharmaceuticals Co., Ltd. | 228 | 2025-01-01 | 2025-01-16 |
| Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT Len+DEB-TACE+HAIC, Len+DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 178 | 2024-08-01 | 2025-01-29 |
| Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC Sin-Bev-TACE, Len-TACE - Hepatocellular Carcinoma Non-resectable | Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 258 | 2023-08-01 | 2023-08-14 |
| Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib - Hepatocellular Carcinoma Non-resectable | Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 187 | 2022-11-02 | 2022-11-08 |
| Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE - Hepatocellular Carcinoma Non-resectable | Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 427 | 2022-11-02 | 2023-05-31 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) ABT-869, Sorafenib - Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | Phase 3 | Terminated | Abbott | 1035 | 2010-01-01 | 2012-09-10 |
Carcinoma, Hepatocellular (4) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Adenocarcinoma (3) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Liver Diseases (3) · Liver Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3)
lenvatinib (2) · Sorafenib (1) · linifanib (1) · sintilimab (1)
Second Affiliated Hospital of Guangzhou Medical University (4) · Abbott (1) · InnoBM Pharmaceuticals Co., Ltd. (1)
China (6) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Italy (1)
Justin Ricker, MD (1) · Kangshun Zhu, MD (1)
2009 (1)